Systematic Exploration of Synergistic Drug Pairs

Drug synergy allows a therapeutic effect to be achieved with lower doses of component drugs. Drug synergy can result when drugs target the products of genes that act in parallel pathways (‘specific synergy’). Such cases of drug synergy should tend to correspond to synergistic genetic interaction between the corresponding target genes. Alternatively, ‘promiscuous synergy’ can arise when one drug non-specifically increases the effects of many other drugs, for example, by increased bioavailability. To assess the relative abundance of these drug synergy types, we examined 200 pairs of antifungal drugs in S. cerevisiae. We found 38 antifungal synergies, 37 of which were novel. While 14 cases of drug synergy corresponded to genetic interaction, 92% of the synergies we discovered involved only six frequently synergistic drugs. Although promiscuity of four drugs can be explained under the bioavailability model, the promiscuity of Tacrolimus and Pentamidine was completely unexpected. While many drug synergies correspond to genetic interactions, the majority of drug synergies appear to result from non-specific promiscuous synergy

Aggregation Policies for Tuple Spaces

International audienceSecurity policies are important for protecting digitalized information, control resource access and maintain secure data storage. This work presents the development of a policy language to transparently incorporate aggregate programming and privacy models for distributed data. We use tuple spaces as a convenient abstraction for storage and coordination. The language has been designed to accommodate well-known models such as k-anonymity and $$(\varepsilon ,\delta )$$(ε,δ)-differential privacy, as well as to provide generic user-defined policies. The formal semantics of the policy language and its enforcement mechanism is presented in a manner that abstracts away from a specific tuple space coordination language. To showcase our approach, an open-source software library has been developed in the Go programming language and applied to a typical coordination pattern used in aggregate programming applications

Instant anonymization

Anonymization-based privacy protection ensures that data cannot be traced back to individuals. Researchers working in this area have proposed a wide variety of anonymization algorithms, many of which require a consid- erable number of database accesses. This is a problem of efficiency especially when the released data is subject to visualization or when the algorithm needs to be run many times to get an acceptable ratio of privacy/utility. In this paper, we present two instant anonymization algorithms for the privacy metrics k-anonymity and l-diversity. Proposed algorithms minimize the number of data accesses by utilizing the summary structure already maintained by the database management system for query selectivity. Experiments on real data sets show that in most cases our algorithm produces an optimal anonymization, and it requires a single scan of data as opposed to hundreds of scans required by the state-of-the-art algorithms

Systematic exploration of synergistic drug pairs

Drug synergy allows a therapeutic effect to be achieved with lower doses of component drugs. Drug synergy can result when drugs target the products of genes that act in parallel pathways (‘specific synergy’). Such cases of drug synergy should tend to correspond to synergistic genetic interaction between the corresponding target genes. Alternatively, ‘promiscuous synergy’ can arise when one drug non-specifically increases the effects of many other drugs, for example, by increased bioavailability. To assess the relative abundance of these drug synergy types, we examined 200 pairs of antifungal drugs in S. cerevisiae. We found 38 antifungal synergies, 37 of which were novel. While 14 cases of drug synergy corresponded to genetic interaction, 92% of the synergies we discovered involved only six frequently synergistic drugs. Although promiscuity of four drugs can be explained under the bioavailability model, the promiscuity of Tacrolimus and Pentamidine was completely unexpected. While many drug synergies correspond to genetic interactions, the majority of drug synergies appear to result from non-specific promiscuous synergy

Systematic exploration of synergistic drug pairs

Drug synergy allows a therapeutic effect to be achieved with lower doses of component drugs. Drug synergy can result when drugs target the products of genes that act in parallel pathways (‘specific synergy'). Such cases of drug synergy should tend to correspond to synergistic genetic interaction between the corresponding target genes. Alternatively, ‘promiscuous synergy' can arise when one drug non-specifically increases the effects of many other drugs, for example, by increased bioavailability. To assess the relative abundance of these drug synergy types, we examined 200 pairs of antifungal drugs in S. cerevisiae. We found 38 antifungal synergies, 37 of which were novel. While 14 cases of drug synergy corresponded to genetic interaction, 92% of the synergies we discovered involved only six frequently synergistic drugs. Although promiscuity of four drugs can be explained under the bioavailability model, the promiscuity of Tacrolimus and Pentamidine was completely unexpected. While many drug synergies correspond to genetic interactions, the majority of drug synergies appear to result from non-specific promiscuous synergy